Leadership
Erez AminovChairman of the Board and Chief Executive Officer
Erez Aminov is the Chairman and Chief Executive Officer of MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA), a clinical-stage biopharmaceutical company at the forefront of developing innovative treatments for neuropsychiatric disorders. Under his leadership, MIRA is advancing transformative therapies such as MIRA55 and Ketamir-2, aiming to address critical unmet medical needs with safe and effective solutions.
With a deep expertise in biotechnology consulting, investment, and leadership, Mr. Aminov has played a pivotal role in shaping the biopharma landscape. Prior to joining MIRA, he founded Locate Venture Corp, where he supported early-stage biotech enterprises and fostered growth through strategic partnerships. He has also served as a trusted consultant for multiple biotech firms and successfully guided two companies through IPOs on the Nasdaq, showcasing his ability to navigate complex financial and regulatory environments.
At MIRA, Mr. Aminov has been instrumental in securing funding, licensing proprietary technologies, and overseeing the submission of Investigational New Drug (IND) applications. His strategic vision continues to position MIRA for success, with pivotal preclinical studies paving the way for clinical advancements.
In addition, Mr. Aminov serves as the Chairman and Chief Executive Officer of Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a biotechnology company dedicated to developing Telomir-1, an innovative therapeutic targeting telomere elongation and protection to treat age- related inflammatory and degenerative conditions.
Mr. Aminov holds a Bachelor of Arts in Accounting from Touro University in New York. His unique blend of financial acumen and forward-thinking leadership drives his mission to advance groundbreaking therapies and deliver value to stakeholders.
With a deep expertise in biotechnology consulting, investment, and leadership, Mr. Aminov has played a pivotal role in shaping the biopharma landscape. Prior to joining MIRA, he founded Locate Venture Corp, where he supported early-stage biotech enterprises and fostered growth through strategic partnerships. He has also served as a trusted consultant for multiple biotech firms and successfully guided two companies through IPOs on the Nasdaq, showcasing his ability to navigate complex financial and regulatory environments.
At MIRA, Mr. Aminov has been instrumental in securing funding, licensing proprietary technologies, and overseeing the submission of Investigational New Drug (IND) applications. His strategic vision continues to position MIRA for success, with pivotal preclinical studies paving the way for clinical advancements.
In addition, Mr. Aminov serves as the Chairman and Chief Executive Officer of Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a biotechnology company dedicated to developing Telomir-1, an innovative therapeutic targeting telomere elongation and protection to treat age- related inflammatory and degenerative conditions.
Mr. Aminov holds a Bachelor of Arts in Accounting from Touro University in New York. His unique blend of financial acumen and forward-thinking leadership drives his mission to advance groundbreaking therapies and deliver value to stakeholders.
Itzchak Angel, PhDChief Scientific Advisor
Itzchak Angel is an accomplished executive in the pharmaceutical industry, with over 40 years’ experience guiding medical, pharmaceutical, drug and business development in both large and emerging companies. Since 2005, he has been President and CEO of Angel Pharmaceutical Consulting & Technologies (A.P.C.T.) where he assists pharmaceutical and biotechnology companies, individuals, medical staff, hospitals, technology transfer companies, investors, university researchers and research teams in variable aspects of drug development. In this role, Dr. Angel provides strategic and operational guidance on issues related to ethical drug development to a wide range of clients, including pharmaceutical and biotechnology companies, medical professionals, hospitals, technology transfer organizations, investors, and research teams. His expertise spans a variety of therapeutic areas and pharmacological families and extends across the drug development process–from research, preclinical and clinical phases, to marketing. In addition, Dr. Angel advises on regulatory affairs, business development, and organizational planning.
Dr. Angel’s journey in the sciences began with his education at the Tel-Aviv University, where he earned his B. Sc, and M.Sc. degrees in Biology in 1979 and 1980, taking part in a special curriculum for outstanding students. He further studied at the Hamburg University, Germany, obtaining a Ph.D. in Neurochemistry in 1982. His postdoctoral research took him to the National Institute of Mental Health in Bethesda, Maryland, where he pursued his research in Neurobiology. For numerous years, he was Head of Pharmacology at Synthelabo (Sanofi-Aventis, Paris, France) where he participated in the research and development of drugs such as Xatral (alfuzosin), Ambien (zolpidem), and Mizollen (mizolastine). Some of Dr. Angel's previous executive roles include President and Chief Executive Officer of the stem-cell company Accellta (Haifa, Israel) and Vice President for Research and Development at Proteologics Ltd, Galmed Pharmaceuticals, and D-Pharm Biopharmaceuticals (Rehovot, Israel), where he was involved in research and advanced development in several areas such as stroke, epilepsy, Alzheimer’s’ Disease, Parkinson’s disease, metabolic disorders, psoriasis, and various cancers.
Dr. Angel has effectively established discovery, research, and development teams and projects, bringing several pharmaceutical drugs to market. As an excellent communicator and negotiator, Dr. Angel has led international projects and worked closely with high-profile regulatory, government, and industry leaders.
Dr. Angel is the author of over 100 book chapters, papers, abstracts, and patents. Outside of his professional work, he is a passionate painter, music lover, and avid traveler who speaks several languages.
Dr. Angel’s journey in the sciences began with his education at the Tel-Aviv University, where he earned his B. Sc, and M.Sc. degrees in Biology in 1979 and 1980, taking part in a special curriculum for outstanding students. He further studied at the Hamburg University, Germany, obtaining a Ph.D. in Neurochemistry in 1982. His postdoctoral research took him to the National Institute of Mental Health in Bethesda, Maryland, where he pursued his research in Neurobiology. For numerous years, he was Head of Pharmacology at Synthelabo (Sanofi-Aventis, Paris, France) where he participated in the research and development of drugs such as Xatral (alfuzosin), Ambien (zolpidem), and Mizollen (mizolastine). Some of Dr. Angel's previous executive roles include President and Chief Executive Officer of the stem-cell company Accellta (Haifa, Israel) and Vice President for Research and Development at Proteologics Ltd, Galmed Pharmaceuticals, and D-Pharm Biopharmaceuticals (Rehovot, Israel), where he was involved in research and advanced development in several areas such as stroke, epilepsy, Alzheimer’s’ Disease, Parkinson’s disease, metabolic disorders, psoriasis, and various cancers.
Dr. Angel has effectively established discovery, research, and development teams and projects, bringing several pharmaceutical drugs to market. As an excellent communicator and negotiator, Dr. Angel has led international projects and worked closely with high-profile regulatory, government, and industry leaders.
Dr. Angel is the author of over 100 book chapters, papers, abstracts, and patents. Outside of his professional work, he is a passionate painter, music lover, and avid traveler who speaks several languages.
Alan Weichselbaum, CPA, MBAChief Financial Officer
Alan Weichselbaum, CPA, MBA, currently serves as Chief Financial Officer of both MIRA Pharmaceuticals, Inc. and Telomir Pharmaceuticals, Inc., bringing over 30 years of experience in corporate finance, capital markets, and strategic advisory across multiple industries. He plays a key leadership role in advancing the financial and strategic objectives of both companies as they pursue growth through drug development, licensing, and potential M&A opportunities.
Since 2015, Mr. Weichselbaum has served as a Director of FinWise Bancorp (Nasdaq: FINW), providing oversight and strategic direction to the publicly traded financial institution. In 2011, he founded The Wexus Group, an outsourced CFO advisory firm that partners with small and mid-sized companies to support growth, capital structuring, and exit strategies across various sectors.
From 1995 to 2010, he held senior roles on Wall Street, where he served as an equity analyst, managed two hedge funds, and was Chief Executive Officer of a boutique brokerage firm. His capital markets expertise and experience leading institutional transactions have positioned him as a trusted advisor in both public and private markets.
Earlier in his career, Mr. Weichselbaum was Manager of Budgeting and Financial Analysis at Philip Morris Capital Corporation. He began his professional journey at Price Waterhouse in 1985, working in the firm’s small business division before pursuing graduate studies.
Mr. Weichselbaum earned his MBA in Finance from New York University and is a Certified Public Accountant licensed in the State of New York. His deep financial acumen, combined with extensive experience in investor relations, capital formation, and M&A, makes him a vital member of the executive leadership at both MIRA and Telomir Pharmaceuticals.
Since 2015, Mr. Weichselbaum has served as a Director of FinWise Bancorp (Nasdaq: FINW), providing oversight and strategic direction to the publicly traded financial institution. In 2011, he founded The Wexus Group, an outsourced CFO advisory firm that partners with small and mid-sized companies to support growth, capital structuring, and exit strategies across various sectors.
From 1995 to 2010, he held senior roles on Wall Street, where he served as an equity analyst, managed two hedge funds, and was Chief Executive Officer of a boutique brokerage firm. His capital markets expertise and experience leading institutional transactions have positioned him as a trusted advisor in both public and private markets.
Earlier in his career, Mr. Weichselbaum was Manager of Budgeting and Financial Analysis at Philip Morris Capital Corporation. He began his professional journey at Price Waterhouse in 1985, working in the firm’s small business division before pursuing graduate studies.
Mr. Weichselbaum earned his MBA in Finance from New York University and is a Certified Public Accountant licensed in the State of New York. His deep financial acumen, combined with extensive experience in investor relations, capital formation, and M&A, makes him a vital member of the executive leadership at both MIRA and Telomir Pharmaceuticals.